Jacobson Center for Clinical & Translational Research

Main Menu


Additional Information


Contact Us

Multiple Myeloma

Study Title:  A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma.  (Identifier: NCT03170882)

Study Purpose:  The purpose of this study is to compare the effect of ixazomib+dexamethasone (ixa+dex) versus pomalidomide+dexamethasone (pom+dex) on progression-free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received at least 2 prior lines of therapy, including lenalidomide and a proteasome inhibitor, and are refractory to lenalidomide but not refractory to proteasome inhibitors.

Principal Investigator: Cherian Verghese, M.D.

Study Coordinator: Stephanie Smiddy, RN for more information, please call 419-383-6962.


Last Updated: 9/11/17